Compare General Mills, Inc. (GIS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? General Mills, Inc. trades at $38.93 (market cap $19.46B), while State Street SPDR S&P Biotech ETF trades at $152.75. The key difference: General Mills, Inc. pays a 6.69% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, General Mills, Inc. nearer its low. Which is the better fit depends on your goals.
| GIS | XBI | |
|---|---|---|
Market Cap | $19.46B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $51.27 | $164.28 |
52-Week Low | $32.17 | $85.16 |
Enterprise Value | $32.95B | — |
Dividend Yield | 6.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $36.46, down 0.38% on the day, with a neutral technical signal and mixed earnings history. The stock shows a low P/E of 9.23 and pays a dividend, but faces net income margin pressure at -0.48% for 2026. Recent news highlights partnerships in regenerative agriculture and cost-saving initiatives targeting $3 billion by 2030 to combat soft consumer demand.
Outlook remains cautious with sales pressure expected in 2027, though valuation appears attractive. Key risks include competitive pressures and margin recovery challenges. Analyst consensus is mixed with a hold-heavy rating, suggesting patience for turnaround execution amid economic headwinds.
XBI trades at $155.19, down 0.23% on the day, with a bullish technical signal from moving averages. Recent news highlights strong biotech sector momentum, with the ETF gaining nearly 17% in a month (24/7 Wall Street, 2026-07-06). Analyst consensus is neutral with a single hold rating, while technical indicators show a neutral RSI and mixed ADX signals. Support is seen near $153, with resistance at $157.
The outlook for XBI is supported by sector strength and M&A activity, but high volatility and a neutral analyst stance suggest cautious optimism. Key risks include regulatory uncertainty and macroeconomic pressures, requiring careful risk management for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
